Exclusive: Johns Hopkins professor and biotech colleagues tout new tech to test Covid-19 vaccine response

Variants to the SARS-CoV-2 virus have emerged of late as yet another threat to a pandemic that’s already killed over 2.2 million people worldwide.

The Covid-19 vaccines already on the market have so far managed to retain at least some level of efficacy in treating new, more infectious strains of the respiratory virus — but concern about other mutations remains palpable as a slow, churning vaccine rollout continues across the globe.